Highlights
KLSE: GENTING (3182)       GENTING BHD MAIN : Consumer
Last Price Today's Change   Day's Range   Trading Volume
4.49   0.00 (0.00%)  4.44 - 4.54  10,304,800
Trade this stock and receive a FREE I3investor T-shirt after 5 trades. Find out more.

Financials


Market Cap: 17,407 Million

Market Cap 17,407 Million
NOSH 3,877 Million

Latest Audited Result:  31-Dec-2022

Latest Audited Result: 31-Dec-2022
Announcement Date 06-Apr-2023
Next Audited Result: 31-Dec-2023
Est. Ann. Date: 06-Apr-2024
Est. Ann. Due Date: 28-Jun-2024

Latest Quarter:  31-Dec-2023 [#4]

Latest Quarter: 31-Dec-2023 [#4]
Announcement Date 29-Feb-2024
Next Quarter: 31-Mar-2024
Est. Ann. Date: 25-May-2024
Est. Ann. Due Date: 30-May-2024
QoQ | YoY   -71.16%  |    188.96%

Annual (Unaudited) ( EPS: 23.97, P/E: 18.73 )

Revenue | NP to SH 27,118,560  |  929,201
RPS | P/RPS 699.49 Cent  |  0.64
EPS | P/E | EY 23.97 Cent  |  18.73  |  5.34%
DPS | DY | Payout % 14.90 Cent  |  3.32%  |  62.16%
NAPS | P/NAPS 8.69  |  0.52
YoY   409.83%
NP Margin | ROE 8.36%  |  2.76%
F.Y. | Ann. Date 31-Dec-2023  |  29-Feb-2024

T4Q Result ( EPS: 23.97, P/E: 18.73 )

Revenue | NP to SH 27,118,560  |  929,201
RPS | P/RPS 699.49 Cent  |  0.64
EPS | P/E | EY 23.97 Cent  |  18.73  |  5.34%
DPS | DY | Payout % 14.90 Cent  |  3.32%  |  62.16%
NAPS | P/NAPS 8.69  |  0.52
QoQ | YoY   52.23%  |    409.83%
NP Margin | ROE 8.36%  |  2.76%
F.Y. | Ann. Date 31-Dec-2023  |  29-Feb-2024

Annualized Result ( EPS: 23.97, P/E: 18.73 )

Revenue | NP to SH 27,118,560  |  929,201
RPS | P/RPS 699.49 Cent  |  0.64
EPS | P/E | EY 23.97 Cent  |  18.73  |  5.34%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -10.55%  |    409.83%
NP Margin | ROE 8.36%  |  2.76%
F.Y. | Ann. Date 31-Dec-2023  |  29-Feb-2024




Show?  YoY % Horiz. %

Last 10 FY Result
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Revenue 27,118,560 27,118,560 27,118,560 22,383,714 13,529,534 11,564,060 21,616,543 20,852,973 20,019,594 18,365,805 18,100,356 18,216,498 4.52%
  YoY % 0.00% 0.00% 21.15% 65.44% 17.00% -46.50% 3.66% 4.16% 9.00% 1.47% -0.64% -
  Horiz. % 148.87% 148.87% 148.87% 122.88% 74.27% 63.48% 118.66% 114.47% 109.90% 100.82% 99.36% 100.00%
PBT 3,567,037 3,567,037 3,567,037 1,265,064 -970,782 -1,526,452 4,582,582 3,418,398 4,312,215 5,459,561 3,445,997 4,262,349 -1.96%
  YoY % 0.00% 0.00% 181.96% 230.31% 36.40% -133.31% 34.06% -20.73% -21.02% 58.43% -19.15% -
  Horiz. % 83.69% 83.69% 83.69% 29.68% -22.78% -35.81% 107.51% 80.20% 101.17% 128.09% 80.85% 100.00%
Tax -1,299,805 -1,299,805 -1,299,805 -1,220,643 -442,305 -547,525 -901,487 -974,529 -1,069,360 -981,731 -848,320 -1,116,223 1.71%
  YoY % 0.00% 0.00% -6.49% -175.97% 19.22% 39.26% 7.50% 8.87% -8.93% -15.73% 24.00% -
  Horiz. % 116.45% 116.45% 116.45% 109.35% 39.63% 49.05% 80.76% 87.31% 95.80% 87.95% 76.00% 100.00%
NP 2,267,232 2,267,232 2,267,232 44,421 -1,413,087 -2,073,977 3,681,095 2,443,869 3,242,855 4,477,830 2,597,677 3,146,126 -3.57%
  YoY % 0.00% 0.00% 5,003.96% 103.14% 31.87% -156.34% 50.63% -24.64% -27.58% 72.38% -17.43% -
  Horiz. % 72.06% 72.06% 72.06% 1.41% -44.92% -65.92% 117.00% 77.68% 103.07% 142.33% 82.57% 100.00%
NP to SH 929,201 929,201 929,201 -299,909 -1,369,646 -1,024,141 1,995,823 1,365,581 1,445,298 2,120,580 1,388,012 1,496,133 -5.15%
  YoY % 0.00% 0.00% 409.83% 78.10% -33.74% -151.31% 46.15% -5.52% -31.84% 52.78% -7.23% -
  Horiz. % 62.11% 62.11% 62.11% -20.05% -91.55% -68.45% 133.40% 91.27% 96.60% 141.74% 92.77% 100.00%
Tax Rate 36.44 % 36.44 % 36.44 % 96.49 % - % - % 19.67 % 28.51 % 24.80 % 17.98 % 24.62 % 26.19 % 3.74%
  YoY % 0.00% 0.00% -62.23% 0.00% 0.00% 0.00% -31.01% 14.96% 37.93% -26.97% -5.99% -
  Horiz. % 139.14% 139.14% 139.14% 368.42% 0.00% 0.00% 75.10% 108.86% 94.69% 68.65% 94.01% 100.00%
Total Cost 24,851,328 24,851,328 24,851,328 22,339,293 14,942,621 13,638,037 17,935,448 18,409,104 16,776,739 13,887,975 15,502,679 15,070,372 5.71%
  YoY % 0.00% 0.00% 11.24% 49.50% 9.57% -23.96% -2.57% 9.73% 20.80% -10.42% 2.87% -
  Horiz. % 164.90% 164.90% 164.90% 148.23% 99.15% 90.50% 119.01% 122.15% 111.32% 92.15% 102.87% 100.00%
Net Worth 33,692,750 33,692,750 33,692,750 31,690,436 31,805,956 32,961,137 35,348,509 34,270,338 33,777,124 33,997,381 32,637,238 26,824,136 2.56%
  YoY % 0.00% 0.00% 6.32% -0.36% -3.50% -6.75% 3.15% 1.46% -0.65% 4.17% 21.67% -
  Horiz. % 125.61% 125.61% 125.61% 118.14% 118.57% 122.88% 131.78% 127.76% 125.92% 126.74% 121.67% 100.00%
Dividend
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Div 577,590 577,590 577,590 616,096 423,566 577,590 847,132 827,879 822,432 465,462 130,102 148,610 16.27%
  YoY % 0.00% 0.00% -6.25% 45.45% -26.67% -31.82% 2.33% 0.66% 76.69% 257.76% -12.45% -
  Horiz. % 388.66% 388.66% 388.66% 414.57% 285.02% 388.66% 570.04% 557.08% 553.42% 313.21% 87.55% 100.00%
Div Payout % 62.16 % 62.16 % 62.16 % - % - % - % 42.45 % 60.62 % 56.90 % 21.95 % 9.37 % 9.93 % 22.59%
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -29.97% 6.54% 159.23% 134.26% -5.64% -
  Horiz. % 625.98% 625.98% 625.98% 0.00% 0.00% 0.00% 427.49% 610.47% 573.01% 221.05% 94.36% 100.00%
Equity
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Net Worth 33,692,750 33,692,750 33,692,750 31,690,436 31,805,956 32,961,137 35,348,509 34,270,338 33,777,124 33,997,381 32,637,238 26,824,136 2.56%
  YoY % 0.00% 0.00% 6.32% -0.36% -3.50% -6.75% 3.15% 1.46% -0.65% 4.17% 21.67% -
  Horiz. % 125.61% 125.61% 125.61% 118.14% 118.57% 122.88% 131.78% 127.76% 125.92% 126.74% 121.67% 100.00%
NOSH 3,850,600 3,850,600 3,850,600 3,850,600 3,850,600 3,850,600 3,850,600 3,850,600 3,825,269 3,723,700 3,717,225 3,715,254 0.40%
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.66% 2.73% 0.17% 0.05% -
  Horiz. % 103.64% 103.64% 103.64% 103.64% 103.64% 103.64% 103.64% 103.64% 102.96% 100.23% 100.05% 100.00%
Ratio Analysis
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
NP Margin 8.36 % 8.36 % 8.36 % 0.20 % -10.44 % -17.93 % 17.03 % 11.72 % 16.20 % 24.38 % 14.35 % 17.27 % -7.74%
  YoY % 0.00% 0.00% 4,080.00% 101.92% 41.77% -205.28% 45.31% -27.65% -33.55% 69.90% -16.91% -
  Horiz. % 48.41% 48.41% 48.41% 1.16% -60.45% -103.82% 98.61% 67.86% 93.80% 141.17% 83.09% 100.00%
ROE 2.76 % 2.76 % 2.76 % -0.95 % -4.31 % -3.11 % 5.65 % 3.98 % 4.28 % 6.24 % 4.25 % 5.58 % -7.52%
  YoY % 0.00% 0.00% 390.53% 77.96% -38.59% -155.04% 41.96% -7.01% -31.41% 46.82% -23.84% -
  Horiz. % 49.46% 49.46% 49.46% -17.03% -77.24% -55.73% 101.25% 71.33% 76.70% 111.83% 76.16% 100.00%
Per Share
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
RPS 704.27 704.27 704.27 581.30 351.36 300.32 561.38 541.55 523.35 493.21 486.93 490.32 4.10%
  YoY % 0.00% 0.00% 21.15% 65.44% 17.00% -46.50% 3.66% 3.48% 6.11% 1.29% -0.69% -
  Horiz. % 143.63% 143.63% 143.63% 118.56% 71.66% 61.25% 114.49% 110.45% 106.74% 100.59% 99.31% 100.00%
EPS 24.13 24.13 24.13 -7.79 -35.57 -26.60 51.83 35.58 38.28 57.00 37.34 40.27 -5.53%
  YoY % 0.00% 0.00% 409.76% 78.10% -33.72% -151.32% 45.67% -7.05% -32.84% 52.65% -7.28% -
  Horiz. % 59.92% 59.92% 59.92% -19.34% -88.33% -66.05% 128.71% 88.35% 95.06% 141.54% 92.72% 100.00%
DPS 15.00 15.00 15.00 16.00 11.00 15.00 22.00 21.50 21.50 12.50 3.50 4.00 15.81%
  YoY % 0.00% 0.00% -6.25% 45.45% -26.67% -31.82% 2.33% 0.00% 72.00% 257.14% -12.50% -
  Horiz. % 375.00% 375.00% 375.00% 400.00% 275.00% 375.00% 550.00% 537.50% 537.50% 312.50% 87.50% 100.00%
NAPS 8.7500 8.7500 8.7500 8.2300 8.2600 8.5600 9.1800 8.9000 8.8300 9.1300 8.7800 7.2200 2.16%
  YoY % 0.00% 0.00% 6.32% -0.36% -3.50% -6.75% 3.15% 0.79% -3.29% 3.99% 21.61% -
  Horiz. % 121.19% 121.19% 121.19% 113.99% 114.40% 118.56% 127.15% 123.27% 122.30% 126.45% 121.61% 100.00%
Adjusted Per Share Value based on latest NOSH - 3,876,896
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
RPS 699.49 699.49 699.49 577.36 348.98 298.28 557.57 537.88 516.38 473.72 466.88 469.87 4.52%
  YoY % 0.00% 0.00% 21.15% 65.44% 17.00% -46.50% 3.66% 4.16% 9.01% 1.47% -0.64% -
  Horiz. % 148.87% 148.87% 148.87% 122.88% 74.27% 63.48% 118.66% 114.47% 109.90% 100.82% 99.36% 100.00%
EPS 23.97 23.97 23.97 -7.74 -35.33 -26.42 51.48 35.22 37.28 54.70 35.80 38.59 -5.15%
  YoY % 0.00% 0.00% 409.69% 78.09% -33.72% -151.32% 46.17% -5.53% -31.85% 52.79% -7.23% -
  Horiz. % 62.11% 62.11% 62.11% -20.06% -91.55% -68.46% 133.40% 91.27% 96.61% 141.75% 92.77% 100.00%
DPS 14.90 14.90 14.90 15.89 10.93 14.90 21.85 21.35 21.21 12.01 3.36 3.83 16.28%
  YoY % 0.00% 0.00% -6.23% 45.38% -26.64% -31.81% 2.34% 0.66% 76.60% 257.44% -12.27% -
  Horiz. % 389.03% 389.03% 389.03% 414.88% 285.38% 389.03% 570.50% 557.44% 553.79% 313.58% 87.73% 100.00%
NAPS 8.6907 8.6907 8.6907 8.1742 8.2040 8.5019 9.1177 8.8396 8.7124 8.7692 8.4184 6.9190 2.56%
  YoY % 0.00% 0.00% 6.32% -0.36% -3.50% -6.75% 3.15% 1.46% -0.65% 4.17% 21.67% -
  Horiz. % 125.61% 125.61% 125.61% 118.14% 118.57% 122.88% 131.78% 127.76% 125.92% 126.74% 121.67% 100.00%
Price Multiplier on Financial Quarter End Date
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Date AQR T4Q 29/12/23 30/12/22 31/12/21 31/12/20 31/12/19 31/12/18 29/12/17 30/12/16 31/12/15 31/12/14 -
Price 4.6200 4.6200 4.6200 4.4800 4.6700 4.4600 6.0500 6.1000 9.2000 8.0000 7.3400 8.8700 -
P/RPS 0.66 0.66 0.66 0.77 1.33 1.49 1.08 1.13 1.76 1.62 1.51 1.81 -10.60%
  YoY % 0.00% 0.00% -14.29% -42.11% -10.74% 37.96% -4.42% -35.80% 8.64% 7.28% -16.57% -
  Horiz. % 36.46% 36.46% 36.46% 42.54% 73.48% 82.32% 59.67% 62.43% 97.24% 89.50% 83.43% 100.00%
P/EPS 19.15 19.15 19.15 -57.52 -13.13 -16.77 11.67 17.20 24.35 14.05 19.66 22.03 -1.54%
  YoY % 0.00% 0.00% 133.29% -338.08% 21.71% -243.70% -32.15% -29.36% 73.31% -28.54% -10.76% -
  Horiz. % 86.93% 86.93% 86.93% -261.10% -59.60% -76.12% 52.97% 78.08% 110.53% 63.78% 89.24% 100.00%
EY 5.22 5.22 5.22 -1.74 -7.62 -5.96 8.57 5.81 4.11 7.12 5.09 4.54 1.56%
  YoY % 0.00% 0.00% 400.00% 77.17% -27.85% -169.54% 47.50% 41.36% -42.28% 39.88% 12.11% -
  Horiz. % 114.98% 114.98% 114.98% -38.33% -167.84% -131.28% 188.77% 127.97% 90.53% 156.83% 112.11% 100.00%
DY 3.25 3.25 3.25 3.57 2.36 3.36 3.64 3.52 2.34 1.56 0.48 0.45 24.55%
  YoY % 0.00% 0.00% -8.96% 51.27% -29.76% -7.69% 3.41% 50.43% 50.00% 225.00% 6.67% -
  Horiz. % 722.22% 722.22% 722.22% 793.33% 524.44% 746.67% 808.89% 782.22% 520.00% 346.67% 106.67% 100.00%
P/NAPS 0.53 0.53 0.53 0.54 0.57 0.52 0.66 0.69 1.04 0.88 0.84 1.23 -8.92%
  YoY % 0.00% 0.00% -1.85% -5.26% 9.62% -21.21% -4.35% -33.65% 18.18% 4.76% -31.71% -
  Horiz. % 43.09% 43.09% 43.09% 43.90% 46.34% 42.28% 53.66% 56.10% 84.55% 71.54% 68.29% 100.00%
Price Multiplier on Announcement Date
AQR T4Q 31/12/23 31/12/22 31/12/21 31/12/20 31/12/19 31/12/18 31/12/17 31/12/16 31/12/15 31/12/14 CAGR
Date AQR T4Q 29/02/24 - 24/02/22 25/02/21 27/02/20 27/02/19 27/02/18 23/02/17 23/02/16 26/02/15 -
Price 4.7700 4.7700 4.7700 4.7100 4.5000 4.6300 5.1600 7.3200 8.9900 9.0800 8.1000 8.9800 -
P/RPS 0.68 0.68 0.68 0.81 1.28 1.54 0.92 1.35 1.72 1.84 1.66 1.83 -10.41%
  YoY % 0.00% 0.00% -16.05% -36.72% -16.88% 67.39% -31.85% -21.51% -6.52% 10.84% -9.29% -
  Horiz. % 37.16% 37.16% 37.16% 44.26% 69.95% 84.15% 50.27% 73.77% 93.99% 100.55% 90.71% 100.00%
P/EPS 19.77 19.77 19.77 -60.47 -12.65 -17.41 9.96 20.64 23.79 15.94 21.69 22.30 -1.33%
  YoY % 0.00% 0.00% 132.69% -378.02% 27.34% -274.80% -51.74% -13.24% 49.25% -26.51% -2.74% -
  Horiz. % 88.65% 88.65% 88.65% -271.17% -56.73% -78.07% 44.66% 92.56% 106.68% 71.48% 97.26% 100.00%
EY 5.06 5.06 5.06 -1.65 -7.90 -5.74 10.04 4.84 4.20 6.27 4.61 4.48 1.36%
  YoY % 0.00% 0.00% 406.67% 79.11% -37.63% -157.17% 107.44% 15.24% -33.01% 36.01% 2.90% -
  Horiz. % 112.95% 112.95% 112.95% -36.83% -176.34% -128.12% 224.11% 108.04% 93.75% 139.96% 102.90% 100.00%
DY 3.14 3.14 3.14 3.40 2.44 3.24 4.26 2.94 2.39 1.38 0.43 0.45 24.08%
  YoY % 0.00% 0.00% -7.65% 39.34% -24.69% -23.94% 44.90% 23.01% 73.19% 220.93% -4.44% -
  Horiz. % 697.78% 697.78% 697.78% 755.56% 542.22% 720.00% 946.67% 653.33% 531.11% 306.67% 95.56% 100.00%
P/NAPS 0.55 0.55 0.55 0.57 0.54 0.54 0.56 0.82 1.02 0.99 0.92 1.24 -8.63%
  YoY % 0.00% 0.00% -3.51% 5.56% 0.00% -3.57% -31.71% -19.61% 3.03% 7.61% -25.81% -
  Horiz. % 44.35% 44.35% 44.35% 45.97% 43.55% 43.55% 45.16% 66.13% 82.26% 79.84% 74.19% 100.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Analyze this stock with MQ Trader system
  39 people like this.
 
keyman Beware of more kitchen sinking on the way. Dont surprise. For G. nothing is impossible. See today 10 richest tycoon list, Lkt almost 掉车尾.
17/04/2024 3:44 PM
AngTayKor When Taurx hosay, LKT will eventually move into top 3 position.
17/04/2024 4:00 PM
sonyx123 something is super wrong with Genting
17/04/2024 4:04 PM
lamkin Let just forget about the Taurx nonsense. The share price will reflect it if it is so true.
17/04/2024 4:05 PM
Riaz1954 People just don’t get it! Genting share price has been underperforming since 2011 well before CV19! Why the underperformance? As i have highlighted, before there are many reasons. Poor governance generally, no change in CEO for last 20+ years despite poor performance. Highest remunerated CEO in Malaysia and other countries as well. Share dumping, in open market by key stakeholders, after dubious announcements, interested party related transactions where by poor performing investments held privately are sold to listed Genting entity, at inflated value, use of impairment charges to manipulate results as these charges often there is lot subjectivity, no promotion of company to generate interest via analysts meetings and holding capital markets day etc. Declaring high dividend when company cant afford it as owners needs cash to purchase other investments or to cover losses, eg like Genting Cruise. Only way price is going to rise any where near 8 RM is if TauRX becomes a reality! Otherwise Genting will continue to under perform even if sales and profits recover!
17/04/2024 5:03 PM
Riaz1954 Genting Group wont be allowed to list in US market as it won’t meet the regulators reporting requirements, and if it did it is more likely to get fined. If it really wants to make Genting attractive then it should look to list in US!
17/04/2024 5:08 PM
AngTayKor Posted by AngTayKor > 1 week ago | Report Abuse

Posted by neohts > | Report Abuse
Just monitor TauRX progress.
AngTayKor, please provide us once you received any update on TauRX.
Very important. Do or die.
-------------

@Neohts, no doubt Taurx is the only hope for this stock to cross above rm10. HMTM confirm can work very well safely but there is "active placebo issue" under double-blinded trial environment. Taurx's success depends on other factors like the corrupted FDA's approval, etc. We may be proven right eventually abt Taurx's true potential in future but an investor can still lose money buying this stock along the way (price dropping back to 4.50, 4.30, 4.00 etc during bad selldowns). Currently, there are many investors that dont believe in the real potential of Taurx and view Taurx as a very small catalyst only. The stock market is a weighing machine in short term with stock price moving up and down. The market is always right so dont try to fight against the market.
-------------------------

Posted by lamkin > 2 hours ago | Report Abuse
Let just forget about the Taurx nonsense. The share price will reflect it if it is so true.

*************


@neohts, what I said earlier corect boh? Most people think Taurx is rubbish. There is a reason why ATK kena "seller's remorse" then bought back those shares that I sold earlier. Im waiting for Q4 UAE CA followed by deals at sideline to be activated. Even then, I believe GenB's share price will hardly reflect it unless LKT decide to lock in the USD billions in profit and sell out his 21% Taurx stake. The SWF can easily absorb LKT's entire 21% stake and they will be very happy to do so.
17/04/2024 6:45 PM
choysun Looks like reversal is imminent. Who managed to top up?
17/04/2024 6:46 PM
choysun @ATK Why would LKT sell if it's likely going to be the Golden Goose. Milk it for years to come la :p
17/04/2024 6:49 PM
OnTime he knows taurx is a 20-yr scam.
17/04/2024 7:16 PM
newbie2019 4.49….. 4.37…..4.26….. 4 again? those day of 8 gelap can’t see
17/04/2024 7:46 PM
choysun I'm also hoping still can get 4 :p
17/04/2024 8:45 PM
AngTayKor Posted by choysun > 4 hours ago | Report Abuse

@ATK Why would LKT sell if it's likely going to be the Golden Goose. Milk it for years to come la :p
------------

GenB currently sitting on over USD1B of unrealised profit on Taurx. After UAE CA when SWF deal's condition is met and activated, LKT can choose to sell his entire 21% stake for abt USD2B cash. Thats abt rm2.50/share of cash. But selling out early means lose future potential big upside. I think LKT probably wont sell any Taurx shares and will choose to hold his winning hand all the way to the end. For retail investor like me, I bet showhand until no money left. Hence, safer to sell a fraction first to take back all my vested capital after UAE CA.
17/04/2024 11:39 PM
AngTayKor Daily Trading Participation
As at 16 April 2024
Participation Net (RM Mil)
Foreign -491
18/04/2024 12:04 AM
AngTayKor Its normal for most investors here to think that Taurx is rubbish or scam when Maybank IB value Taurx at usd1b only, meaning GenB is sitting on losses for their Taurx investment.
18/04/2024 12:09 AM
neohts Is our own mistake, even if next month the share price go up to 5, we also won't sell thinking of TauRX. Then later down again.
Nobody know when TauRX could approved.
It is sad to see the price up and down from 5 to 4.46 so many time.
18/04/2024 8:15 AM
choysun Good for traders ma. 10% every cycle :p
18/04/2024 9:04 AM
troy88 This genting seems like always jinx in this state..
18/04/2024 10:17 AM
newbie2019 melting down to 4.37
18/04/2024 10:22 AM
AngTayKor @neohts, i believe in the potential of Taurx. But i have bought n sold GenB for so many rounds already. In fact last month i promptly reminded a few times here that the taurx news is just 24 mth result n not approval yet so dont get too carried away.
18/04/2024 10:23 AM
newbie2019 no supports…. 4 will be good supports lol
18/04/2024 10:23 AM
troy88 There are other better stocks to make money than playing yoyo with Genting
18/04/2024 10:27 AM
Bochiakak Bought at 4.50 as expected after a long wait. Next waiting price is 4.00. Sure can get cos spent another 1B trying to get another casino licence. Once got 4.00, ready for the coming AGM
18/04/2024 10:33 AM
Bochiakak Taurx is just play play. Dont get over excited over it. Approval is still a long way to go. Forget abt it
18/04/2024 10:36 AM
Ytl2023 Coming 4.40. Thailand open new casino. Sure hailat. Which tourist come Malaysia. Malaysia own people like to go Thailand also
18/04/2024 10:38 AM
Ytl2023 Yes LKT sure want share taurx with u. Give u empire got la
18/04/2024 10:41 AM
OTB Posted by AngTayKor > 14 minutes ago | Report Abuse

@neohts, i believe in the potential of Taurx. But i have bought n sold GenB for so many rounds already. In fact last month i promptly reminded a few times here that the taurx news is just 24 mth result n not approval yet so dont get too carried away.
------------------
Even it is not approved, can the company sells this drug to make profit ?
The US is not a gentleman country, she will delay the final approval unless it is an US drug company.
Please advise.
Thank you.
18/04/2024 10:43 AM
lamkin Don't be naive to believe Taurx will have any benefit to Genting, LKT will make way to pocket it to his private entity.
18/04/2024 10:44 AM
Ytl2023 Those bought rm4.50- 4.60. Can average again
18/04/2024 10:47 AM
troy88 Taurx so far is proven to be all hype and no substance
18/04/2024 10:51 AM
OnTime genting =/= 云顶. genting == abyss.
18/04/2024 11:27 AM
Junichiro TAURX is a UK company. Genting is one of its shareholders.
18/04/2024 12:08 PM
prudentinvestor Buy bank counters if you want to sleep well.
18/04/2024 12:27 PM
AngTayKor Posted by Junichiro > 17 minutes ago | Report Abuse

TAURX is a UK company. Genting is one of its shareholders.
----------

Actually its a singapore company but base in UK
18/04/2024 12:27 PM
AngTayKor If no approval, of course much harder to sell the drug. However, HMTM is now available at HK under paid compassionate program. Taurx now applying to expand this program to other China territories like Macau guangdong region.

Unless LKT willing to sell out his 21% stake to SWF n crystalise the usd2b investment (probable value then) into cash after UAE CA, else its just a paper profit not even reflected in accounting books (probably still recorded at cost price).

Abt USA FDA, I believe its easier for FDA to approve weak problematic drugs developed by American pharmas like Biogen / Eli, than to reject a good drug with no side effects (especially after Tofersen's approval has opened a precedence for HMTM to follow using the AA pathway).
18/04/2024 12:30 PM
Junichiro @ATK.. Thanks for enlightening me.
18/04/2024 12:31 PM
neohts AngTayKor,
HMTM is now available at HK under paid compassionate program. Taurx now applying to expand this program to other China territories like Macau guangdong region.

Can TauRX selling in China and south east Asia even without approval from FDA ?
18/04/2024 12:36 PM
AngTayKor Just look at mci patient group. At 18 mths we are still able to reversal back upwards n performing above the initial start point scores. Lecanemab can only slowdown by 27% n still declining at 73% + brain bleeding + brain shrinkage. HMTM can stop the decline + reverse back upwards.
18/04/2024 12:36 PM
AngTayKor @neohts, if no FDA approval but secure EMA CA, I believe can eventually sell to most territories except USA. Countries can also choose to follow EMA's decision.
18/04/2024 12:41 PM
investopology genting really hit the 4.44 to close the gap. might rebounding next week. and after the good news announce and good QR coming it should be able to rebound soon.
18/04/2024 1:27 PM
Boon Keng Genting operator cunning, purposesly press down to let shareholder throw and they collect back your cheap ticket. and give u dividend as sweet of memories.
18/04/2024 1:28 PM
EngineeringProfit Can slowly recollect fro another ride.....no hurry
18/04/2024 1:29 PM
VincentTang Genting Singapore start reverse from botton and up 3.3% today. Is time to buy GENM and GENTING now.
18/04/2024 1:43 PM
AngTayKor Posted by prudentinvestor > 1 hour ago | Report Abuse
Buy bank counters if you want to sleep well.
-------------

Powell backing away from rate cuts good for banking stocks
18/04/2024 2:08 PM
AngTayKor GenS moving up in anticipation of MBS result next week
18/04/2024 2:09 PM
speakup Almost want cut loss at 4.40. Good thing didn't hit cut loss
18/04/2024 3:56 PM
Shines GenS AGm, fixing div dates
18/04/2024 4:04 PM
neohts Still no strong support. Too many seller at the end of the day. Buyer keep buying selling keep showing up.
18/04/2024 8:49 PM
AngTayKor Could be an illusion to create mkt confusion? 😀

I like to see my "sister's behaviour" sometimes.
18/04/2024 9:06 PM
newbie2019 erh…. where is my 4.37
18/04/2024 9:39 PM